Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
This review examines how GLP-1 receptor agonists may influence neurodegenerative disease biology through metabolic, ...
HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...
DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced completion of enrollment in the open-label portion of its ...
DUBLIN--(BUSINESS WIRE)-- Theravance Biopharma, Inc. (TBPH) today announced the launch of “Power in the Periphery,” a new disease education campaign for healthcare professionals (HCPs) to raise ...
Alterity Therapeutics has outlined three priorities for 2026 following the successful completion in 2025 of a Phase II trial of ... Read More The post Alterity gears up for Phase III MSA trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results